The company will test whether ALRN-6924 can protect patients with TP53-mutated small-cell lung cancer from the off-target effects of chemotherapy topotecan.
In a Phase Ia/Ib study, the anti-TIGIT antibody and Tecentriq combination had better anti-tumor activity than tiragolumab alone, particularly in PD-L1 expressing lung cancers.
Two studies presented at ASCO's virtual annual meeting demonstrated the clinical utility of germline findings in guiding treatment decisions in cancer.
The studies highlighted the activity of three drugs in NSCLC patients characterized by HER2 mutations, CECAM5 overexpression, and high PD-L1 expression.
ArcherDx will develop sequencing-based circulating tumor DNA assays for use in AstraZeneca's recently launched Phase III MERMAID-1 trial of durvalumab (Imfinzi).
One cohort will involve NSCLC patients with MET exon 14 skipping mutations, while two other cohorts will enroll patients with solid tumors with MET amplifications and fusions.
The Shanghai-based molecular diagnostics firm is working with the Shanghai Zhongshan Hospital and other medical centers to enroll patients into the PREDICT trial.
The company, which recently wrapped enrollment for a Phase II trial in China, is continuing to actively enroll patients in the US trial for the drug despite the COVID-19 pandemic.
